The Gavi Alliance Board:

a) **Appointed** the following Board Members:
   
   - **Irene Koek** of the United States as Board Member representing the United States on the donor constituency anchored by the United States in the seat currently held by Katie Taylor of the United States effective immediately and until 30 June 2017.
   
   - **Helen Rees** as an Unaffiliated Board Member in the seat currently held by Sania Nishtar effective immediately until 30 June 2019.
   
   - **Ramjanam Chaudhary** of Nepal representing the developing country constituency in the seat currently held by Khaga Raj Adhikari of Nepal effective immediately and until 31 December 2017.
   
   - **David Loew** as a Board Member representing the vaccine industry industrialised countries in the seat currently held by Olivier Charmeil effective immediately and until 31 July 2017.
b) **Reappointed** the following Board Member:
   - **Donal Brown** of the United Kingdom as Board Member representing the United Kingdom on the donor constituency anchored by the United Kingdom until 31 December 2016.

c) **Appointed** the following Alternate Board Member:
   - **Jason Lane** of the United Kingdom as Alternate Board Member to Donal Brown of the United Kingdom, representing the donor constituency anchored by the United Kingdom, in the seat currently held by Jo-Ann Purcell of Canada effective immediately and until 31 December 2016.
   - **Bounkong Syhavong** of Lao PDR as Alternate Board Member to Ramjanam Chaudhary of Nepal representing the developing country constituency in the seat currently held by Eksavang Vongvichit of Lao PDR effective immediately and until 31 December 2017.
d) **Appointed** the following to the Executive Committee effective 1 July 2016:
   • Donal Brown until 31 December 2016.

e) **Appointed** the following to the Governance Committee effective 1 July 2016:
   • Donal Brown until 31 December 2016.

f) **Appointed** the following to the Audit and Finance Committee effective immediately:
   • Alexandru Cebotari (Committee Delegate) until 31 December 2017.
   • Emmanuel Maina Djoulde (Committee Delegate) until 31 December 2017.
g) **Appointed** the following to the Programme and Policy Committee effective immediately:

- **Helen Rees** (Board Member) in the seat currently held by Sania Nishtar (Board Member) until 31 December 2017.
- **Brad Gessner** (Alternate Board Member) in the seat currently held by Zulfiqar A. Bhutta (Committee Delegate) until 31 December 2017.
- **Rama Lakshminarayanan** (Alternate Board Member) in the seat currently held by Robert Oelrichs (Committee Delegate) until 31 December 2017.
- **Syed Monjurul Islam** (Committee Delegate) in the seat currently held by Shanta Bahadur Shresta (Committee Delegate) until 31 December 2017.
The Gavi Alliance Board:

- **Approved** amendments to the Board Travel Policy as outlined in Appendix 1 to Doc 02b.
The Gavi Alliance Board **approved**:

a) the appointment for a term of three years of Professor Dr. Claude Rouiller as President of the Gavi Ad Hoc Appeals Tribunal; and

b) the appointment for a term of three years of Ms Anne Trebilcock as legal expert to serve on the Gavi Ad Hoc Appeals Tribunal in case of unavailability of its President.
The Gavi Alliance Board:

Programmes

a) **Approved** the recommendations of the March 2016 New Proposals IRC for new rotavirus programme in Lesotho to commence in 2017.

Budgets

b) **Endorsed** a net increase in programme budgets by US$ 0.2 million for the period 2017 to implement the IRC recommendations in (a).

These endorsements would constitute acknowledgement of such budget amounts but would not constitute a funding approval, decision, obligation or commitment of the Gavi Alliance or its contributors.
The Gavi Alliance Board:

- **Agreed** to a portion of the already approved Gavi contribution to the global oral cholera vaccine stockpile being used for operational costs for Gavi-supported countries (low income, Phase 1 and Phase 2 countries), for which the estimated costs are US$ 20 million in the period 2016-2018.
The Gavi Alliance Board:

- **Approved** an amount of up to US$ 15 million of bridge funding to meet meningitis emergency outbreak needs of the 26 countries in the African meningitis belt in the 2016-2017 and 2017-2018 transmission seasons to be managed through the Meningitis International Coordination Group (ICG). The bridge funding amount includes estimated costs for the procurement of polysaccharide and conjugate vaccines, devices and shipment and operational cost.
DECISION 7: CONSENT AGENDA: CO-FINANCING OF JAPANESE ENCEPHALITIS VACCINE

The Gavi Alliance Board:

• **Agreed** that Gavi and countries shall co-finance Japanese Encephalitis vaccine used in routine vaccination programmes.
DECISION 8: VICE CHAIR APPOINTMENT

The Gavi Alliance Board:

- **Reappointed** the current Board Vice Chair, **Flavia Bustreo**, for a second term as Board Vice Chair initially to 30 June 2017.
DECISION 9: MALARIA VACCINE PILOTS (1/2)

The Gavi Alliance Board, using available resources from the current strategic period, and contingent upon WHO securing funding from other sources to fully finance the Malaria Vaccine Pilots:

a) **Approved** in principle an amount of up to US$ 27.5 million (equivalent to half of the funding request) for Phase 1 of the WHO-led Malaria Vaccine pilots to be implemented during 2017-2020; and
DECISION 9: MALARIA VACCINE PILOTS (2/2)

b) **Noted** that this investment is contingent upon:

i. Other funders contributing an equivalent amount to cover the pilot costs

ii. Independent review of the proposed budget amount ensuring that this is being done as cost effectively as possible

iii. Further assessment of the selection of pilot settings

iv. Close engagement with the Global Fund and UNITAID including through the proposed Funders Forum

v. WHO seeking input from Alliance partners in the planning and implementation of the pilots

vi. Communication that this investment is for implementation evaluation of a newly licensed vaccine as distinct from R&D

vii. Clear communication that this recommendation does not constitute a precedent for future funding related to the implementation of the malaria vaccine regardless of the outcome of the pilots, nor for future funding of similar pilots for other vaccines

viii. Quarterly reports, including active monitoring of key risks, to the PPC, and a detailed report to the PPC and Board on progress no later than 2019
The Gavi Alliance Board:

a) **Approved** the Framework guiding implementation of Gavi’s Health System and Immunisation Strengthening support attached as Annex A to Doc 04 to the PPC;

b) **Approved** the Implications for previous Board decisions and Board-approved policies, as well as the implementation plans as set out in Annex B attached to Doc 04 to the PPC, noting that the PPC recommended implementation immediately following the Board decision, taking into account feasibility for countries and realistic timelines for ensuring smooth and efficient scale up of implementation;

c) **Approved** the modifications to Gavi’s Co-Financing Policy regarding co-financing for measles and measles-rubella follow-up campaigns as set out in Appendix 2 to Doc 12;

d) **Agreed** that an amount of at least US$ 1.3 billion is available for HSS disbursements (including performance payments) for grant programme years in the 2016-2020 strategic period, with additional funding being subject to future Board decisions.
The Gavi Alliance Board:

- **Approved** the Supply and Procurement Strategy 2016-2020 attached as Annex A and the Strategy Annexes attached as Annex B to Doc 06 to the PPC.